A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
Trial details
- Registry ID
- NCT07568535
- Drugs studied
- Remestemcel-L-rknd